Prednisone microencapsulated - Orbis Biosciences
Alternative Names: ORB-101; Prednisone microencapsulatedLatest Information Update: 14 Jan 2022
At a glance
- Originator Orbis Biosciences
- Developer Childrens Mercy Hospital Kansas City; Orbis Biosciences
- Class Anti-inflammatories; Antiallergics; Antineoplastics; Antirheumatics; Corticosteroids; Glucocorticoids; Pregnadienediols; Small molecules
- Mechanism of Action Glucocorticoid receptor agonists; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Asthma; Atopic dermatitis; Bronchitis; Cancer; Eczema; Nephrotic syndrome
Most Recent Events
- 28 May 2021 No recent reports of development identified for phase-I development in Asthma(In volunteers) in USA (PO, Powder)
- 28 May 2021 No recent reports of development identified for phase-I development in Atopic-dermatitis(In volunteers) in USA (PO, Powder)
- 28 May 2021 No recent reports of development identified for phase-I development in Bronchitis(In volunteers) in USA (PO, Powder)